20 June 2013
Keywords: sym001, enters, ph, itp, hdn, trial, danish
Article | 19 March 2007
Danish biopharmaceutical firm Symphogen and Sweden's Biovitrum have initiated a Phase I clinical trial of their developmental antibody drug
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 March 2007
19 June 2013
© 2013 thepharmaletter.com